Insmed Incorporated
INSM
주식 순위
#1117
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
주가
$93.98
마지막 동기화: 2026-10-21
시가총액
$20.52B
변동 (1일)
-1.77%
변동 (1년)
-41.41%
국가
US
거래 Insmed Incorporated (INSM)
카테고리
Healthcare
Insmed Incorporated (INSM)의 주가 이력
최고 종가: $100.34 (2026-10-01 기준)
최저 종가: $139.94 (2000-06-01 기준)
최저 종가: $139.94 (2000-06-01 기준)
Insmed Incorporated의 주가 이력 (2000 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -25.88% |
| 2025 | 163.90% |
| 2024 | 150.02% |
| 2023 | 48.62% |
| 2022 | -29.22% |
| 2021 | -27.29% |
| 2020 | 59.86% |
| 2019 | 62.30% |
| 2018 | -51.70% |
| 2017 | 128.88% |
| 2016 | -24.86% |
| 2015 | 16.87% |
| 2014 | -8.76% |
| 2013 | 145.55% |
| 2012 | 112.00% |
| 2011 | -49.13% |
| 2010 | -19.73% |
| 2009 | 46.16% |
| 2008 | -42.34% |
| 2007 | -13.04% |
| 2006 | -35.82% |
| 2005 | -15.49% |
| 2004 | -33.15% |
| 2003 | 447.28% |
| 2002 | -85.64% |
| 2001 | 16.21% |
| 2000 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.89 | -3.74% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
